Tag: postherpetic neuralgia (phn) market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Postherpetic Neuralgia (PHN) Market Size Forecast: How Big Could The Market Get By 2030?#_x000D_

The postherpetic neuralgia (phn) market size has experienced robust expansion in recent years. It is projected to increase from $0.77 billion in 2025 to $0.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this growth can be attributed to several factors, including an escalating incidence of herpes zoster infections, the limited availability of treatment options for neuropathic pain, a prevalent reliance on opioid-based pain management strategies, an expanding elderly population, and the gradual broadening of hospital-based pain management services._x000D_

_x000D_

The market size for postherpetic neuralgia (phn) is expected to demonstrate robust expansion in the coming years. It is projected to increase to $1.06 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.5%. This anticipated growth can be attributed to several factors including the creation of targeted neuropathic pain treatments, the increasing uptake of biologic and branded pharmaceutical products, the expansion of online pharmacy distribution channels, a heightened focus on patient-centric pain management strategies, and the proliferation of outpatient and ambulatory care facilities. Prominent trends for the forecast period include the rising incidence of shingles within the aging population, a greater adoption of non-opioid pain management therapies, the increasing utilization of transdermal and topical pain relief solutions, a higher demand for long-term chronic pain management, and enhanced awareness alongside earlier diagnosis of phn._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=43705044&type=smp&name=Postherpetic%20Neuralgia%20%28PHN%29%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Postherpetic Neuralgia (PHN) Market Growth Drivers: What’s Behind The Acceleration?#_x000D_

The rising occurrence of chronic pain conditions is anticipated to drive the expansion of the postherpetic neuralgia (PHN) market in the future. Chronic pain is defined as discomfort that is ongoing or reoccurring for over three months, frequently extending past the typical recovery period of a sickness or wound, thereby impacting an individual’s everyday activities and overall well-being. The widespread nature of chronic pain conditions stems from the aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in enduring pain. Postherpetic neuralgia offers valuable assistance for chronic pain research by presenting a distinct framework for investigating nerve-associated pain processes and assessing prolonged treatment approaches. For example, a January 2024 report from the Office for Health Improvement and Disparities, a government body in the UK, indicated that approximately 18.4% of individuals aged 16 and over stated they had a long-term musculoskeletal (MSK) condition in 2023, which was an increase from 17.6% in 2022. Consequently, the rising occurrence of chronic pain conditions is propelling the development of the postherpetic neuralgia (PHN) market._x000D_

_x000D_

#Postherpetic Neuralgia (PHN) Market Segment Breakdown: Which Categories Lead On Revenue?#_x000D_

The postherpetic neuralgia (phn) market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Patches, Drugs, Opioids_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

3) By End Users: Hospitals, Clinics, Other End Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches_x000D_

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs_x000D_

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists_x000D_

_x000D_

#Postherpetic Neuralgia (PHN) Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_

Leading companies active in the postherpetic neuralgia (PHN) market are concentrating on securing regulatory clearances to broaden their product offerings, gain a competitive edge, and address the substantial unmet clinical demand for more efficacious and tolerable treatments. Regulatory approvals denote the official permissions granted by governmental health bodies that allow a drug or therapy to be lawfully marketed and utilized for a particular medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, obtained final approval from the United States Food and Drug Administration to produce and commercialize once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, designated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a type of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing begins with 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as required for pain relief._x000D_

_x000D_

#Postherpetic Neuralgia (PHN) Market Leading Players And Competitive Positioning#_x000D_

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd. _x000D_

_x000D_

#View The Full Postherpetic Neuralgia (PHN) Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Postherpetic Neuralgia (PHN) Market Geographic Distribution And Regional Opportunities#_x000D_

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Postherpetic Neuralgia (PHN) Market Over The Forecast Period?

The market for postherpetic neuralgia (phn) has seen robust growth in recent years. It is projected to increase from $0.77 billion in 2025 to $0.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. This historical expansion can be attributed to factors such as the increasing incidence of herpes zoster infections, limited available treatment options for neuropathic pain, a prevalent reliance on opioid-based pain management, the expanding elderly population, and the gradual growth of hospital pain management services.

The postherpetic neuralgia (phn) market size is anticipated to show significant expansion in the next few years, projected to reach $1.06 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is attributed to the development of targeted neuropathic pain therapies, the rising adoption of biologic and branded drugs, the expansion of online pharmacy distribution channels, an increasing focus on patient-centric pain management, and the growth of outpatient and ambulatory care facilities. Prominent trends expected in this period include the rising prevalence of shingles in the aging population, the increasing adoption of non-opioid pain management therapies, the growing use of transdermal and topical pain relief solutions, a higher demand for long-term chronic pain management, and improved awareness and early diagnosis of phn.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Important Drivers Are Powering The Postherpetic Neuralgia (PHN) Market Growth?

The rising occurrence of chronic pain conditions is anticipated to drive the expansion of the postherpetic neuralgia (PHN) market in the future. Chronic pain is defined as enduring or repeated discomfort that persists for over 3 months, frequently extending past the typical duration of a sickness or wound, thereby impacting an individual’s daily activities and overall well-being. The widespread presence of chronic pain conditions stems from the aging demographic, given that seniors are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in ongoing pain. Postherpetic neuralgia proves beneficial for chronic pain investigations because it offers a distinct framework for examining nerve-associated pain pathways and assessing prolonged therapeutic approaches. As an illustration, in January 2024, data from a report issued by the Office for Health Improvement and Disparities, a UK government body, indicated that approximately 18.4% of individuals aged 16 and over reported suffering from a long-term musculoskeletal (MSK) condition in 2023, representing an increase from 17.6% in 2022. Consequently, the growing occurrence of chronic pain conditions is fueling the expansion of the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Distributed Across Key Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

Which Trends Are Shaping The Postherpetic Neuralgia (PHN) Market Landscape?

Leading companies in the postherpetic neuralgia (PHN) market are focusing on securing regulatory approvals to broaden their product offerings, gain a competitive edge, and address the considerable unmet clinical need for more effective and tolerable treatments. Regulatory approvals signify the official permissions granted by governmental health bodies, allowing a drug or therapy to be legally marketed and used for a specific medical condition. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, obtained final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are designed for treating PHN, which is a form of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing begins with 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as necessary for pain relief.

Which Firms Are Competing In The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Access The Complete Postherpetic Neuralgia (PHN) Market Report:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is The Dominant Market In The Postherpetic Neuralgia (PHN) Market?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Postherpetic Neuralgia (PHN) Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Postherpetic Neuralgia (PHN) Market Expected To Reach Based On Its 2026 Value?

The postherpetic neuralgia (phn) market has experienced significant growth in recent years. It is anticipated to increase from $0.77 billion in 2025 to $0.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The historical expansion of this market can be attributed to elements such as an escalating incidence of herpes zoster infections, a scarcity of treatment alternatives for neuropathic pain, a reliance on opioid-based pain management strategies, an expanding elderly demographic, and the progressive development of hospital pain management provisions.

The market for postherpetic neuralgia (phn) is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $1.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors driving this growth during the projected period include the emergence of targeted neuropathic pain treatments, increased use of biologic and branded medications, the expansion of online pharmacy distribution networks, a heightened emphasis on patient-centered pain management strategies, and the proliferation of outpatient and ambulatory care facilities. Key trends anticipated within this timeframe encompass the increasing incidence of shingles among the elderly population, a greater shift towards non-opioid pain relief methods, the expanding application of transdermal and topical solutions for pain, a surging need for sustained chronic pain management, and enhanced understanding leading to earlier detection of phn.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Leading Drivers Are Supporting The Postherpetic Neuralgia (PHN) Market Expansion?

The postherpetic neuralgia (PHN) market is anticipated to experience growth driven by the rising prevalence of chronic pain conditions. Chronic pain is characterized by persistent or recurring discomfort lasting over three months, often extending beyond the typical recovery period from an illness or injury, thus affecting an individual’s daily functioning and quality of life. This widespread occurrence of chronic pain is attributed to the aging population, as older adults are more prone to degenerative ailments like arthritis and neuropathy that lead to sustained pain. Postherpetic neuralgia proves beneficial for chronic pain research by providing a clear model for studying nerve-related pain mechanisms and evaluating long-term treatment strategies. For example, in January 2024, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that about 18.4% of people aged 16 and over reported having a long-term musculoskeletal (MSK) condition in 2023, which was an increase from 17.6% in 2022. Hence, the increasing prevalence of chronic pain conditions is propelling the growth of the postherpetic neuralgia (PHN) market.

Which Segment Classifications Are Used In The Postherpetic Neuralgia (PHN) Market Segment Analysis?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Trends Are Affecting The Direction Of The Postherpetic Neuralgia (PHN) Market?

Leading companies within the postherpetic neuralgia (PHN) market are prioritizing the acquisition of regulatory clearances to broaden their product offerings, gain a competitive edge, and address the substantial unmet clinical demand for more efficacious and tolerable treatments. Regulatory approvals denote the formal authorizations issued by governmental health authorities, enabling a drug or therapy to be legally sold and utilized for a specific medical condition. As an illustration, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical enterprise, secured final approval from the United States Food and Drug Administration to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, specifically indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a form of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing begins with 300 mg on the initial day, increases to 600 mg (300 mg twice daily) on the second day, and reaches 900 mg (300 mg three times daily) on the third day, with titration possible up to a maximum of 1800 mg per day (600 mg three times daily) as necessary for pain relief.

Which Firms Are Contributing To The Postherpetic Neuralgia (PHN) Market Ecosystem?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Get The Full Postherpetic Neuralgia (PHN) Market Report:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Dominates The Postherpetic Neuralgia (PHN) Market By Market Share?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Postherpetic Neuralgia (PHN) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Postherpetic Neuralgia (PHN) Market Over The Period 2026–2030?

The postherpetic neuralgia (phn) market has experienced robust expansion over recent years. Forecasts indicate it will expand from $0.77 billion in 2025 to reach $0.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this expansion has been driven by factors such as a rising occurrence of herpes zoster infections, insufficient therapeutic choices for neuropathic pain, dependence on opioid-centric pain management, an expanding older demographic, and the progressive broadening of hospital pain management services.

The postherpetic neuralgia (phn) market is poised for significant expansion in the coming years, with projections indicating a rise to $1.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is largely driven by the development of targeted neuropathic pain therapies, increased adoption of biologic and branded drugs, the proliferation of online pharmacy distribution channels, a heightened focus on patient-centric pain management approaches, and the expansion of outpatient and ambulatory care facilities. Furthermore, major trends anticipated in this period include the rising prevalence of shingles within the aging population, a growing preference for non-opioid pain management therapies, the increasing utilization of transdermal and topical pain relief solutions, a greater demand for long-term chronic pain management strategies, and improved awareness coupled with earlier diagnosis of phn.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Underlying Factors Are Accelerating The Growth Of The Postherpetic Neuralgia (PHN) Market?

The escalating occurrence of chronic pain conditions is projected to fuel the expansion of the postherpetic neuralgia (PHN) market in the foreseeable future. Chronic pain is defined as pain that persists or recurs for over 3 months, frequently extending beyond the typical duration of an illness or injury and negatively impacting an individual’s daily activities and overall well-being. The widespread presence of chronic pain conditions stems from the aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in ongoing pain. Postherpetic neuralgia serves as a valuable area for chronic pain research because it offers a distinct model for investigating nerve-related pain processes and assessing extended treatment approaches. For example, a report released in January 2024 by the Office for Health Improvement and Disparities, a UK government body, indicated that approximately 18.4% of individuals aged 16 and above reported experiencing a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the rising occurrence of chronic pain conditions is a significant factor propelling the expansion of the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Divided Into Its Major Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

How Are Trends Transforming The Postherpetic Neuralgia (PHN) Market Landscape?

Major companies in the postherpetic neuralgia (PHN) market are concentrating on obtaining regulatory clearances to expand their product lines, gain a competitive edge, and address the considerable unmet clinical need for more effective and tolerable treatments. Regulatory approvals refer to the official authorizations issued by government health authorities that allow a drug or therapy to be legally sold and used for a specific medical condition. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, secured final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a type of neuropathic pain arising from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing starts at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

Who Are The Prominent Organizations Shaping The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Read the full postherpetic neuralgia (phn) market report here:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is Projected To Dominate The Postherpetic Neuralgia (PHN) Market During The Forecast Period?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Postherpetic Neuralgia (PHN) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Postherpetic Neuralgia (PHN) Market Over The Period 2026–2030?

The postherpetic neuralgia (phn) market has experienced robust expansion over recent years. Forecasts indicate it will expand from $0.77 billion in 2025 to reach $0.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this expansion has been driven by factors such as a rising occurrence of herpes zoster infections, insufficient therapeutic choices for neuropathic pain, dependence on opioid-centric pain management, an expanding older demographic, and the progressive broadening of hospital pain management services.

The postherpetic neuralgia (phn) market is poised for significant expansion in the coming years, with projections indicating a rise to $1.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is largely driven by the development of targeted neuropathic pain therapies, increased adoption of biologic and branded drugs, the proliferation of online pharmacy distribution channels, a heightened focus on patient-centric pain management approaches, and the expansion of outpatient and ambulatory care facilities. Furthermore, major trends anticipated in this period include the rising prevalence of shingles within the aging population, a growing preference for non-opioid pain management therapies, the increasing utilization of transdermal and topical pain relief solutions, a greater demand for long-term chronic pain management strategies, and improved awareness coupled with earlier diagnosis of phn.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Underlying Factors Are Accelerating The Growth Of The Postherpetic Neuralgia (PHN) Market?

The escalating occurrence of chronic pain conditions is projected to fuel the expansion of the postherpetic neuralgia (PHN) market in the foreseeable future. Chronic pain is defined as pain that persists or recurs for over 3 months, frequently extending beyond the typical duration of an illness or injury and negatively impacting an individual’s daily activities and overall well-being. The widespread presence of chronic pain conditions stems from the aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in ongoing pain. Postherpetic neuralgia serves as a valuable area for chronic pain research because it offers a distinct model for investigating nerve-related pain processes and assessing extended treatment approaches. For example, a report released in January 2024 by the Office for Health Improvement and Disparities, a UK government body, indicated that approximately 18.4% of individuals aged 16 and above reported experiencing a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the rising occurrence of chronic pain conditions is a significant factor propelling the expansion of the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Divided Into Its Major Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

How Are Trends Transforming The Postherpetic Neuralgia (PHN) Market Landscape?

Major companies in the postherpetic neuralgia (PHN) market are concentrating on obtaining regulatory clearances to expand their product lines, gain a competitive edge, and address the considerable unmet clinical need for more effective and tolerable treatments. Regulatory approvals refer to the official authorizations issued by government health authorities that allow a drug or therapy to be legally sold and used for a specific medical condition. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, secured final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a type of neuropathic pain arising from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing starts at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

Who Are The Prominent Organizations Shaping The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Read the full postherpetic neuralgia (phn) market report here:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is Projected To Dominate The Postherpetic Neuralgia (PHN) Market During The Forecast Period?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Postherpetic Neuralgia (PHN) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Postherpetic Neuralgia (PHN) Market Over The Period 2026–2030?

The postherpetic neuralgia (phn) market has experienced robust expansion over recent years. Forecasts indicate it will expand from $0.77 billion in 2025 to reach $0.82 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historically, this expansion has been driven by factors such as a rising occurrence of herpes zoster infections, insufficient therapeutic choices for neuropathic pain, dependence on opioid-centric pain management, an expanding older demographic, and the progressive broadening of hospital pain management services.

The postherpetic neuralgia (phn) market is poised for significant expansion in the coming years, with projections indicating a rise to $1.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is largely driven by the development of targeted neuropathic pain therapies, increased adoption of biologic and branded drugs, the proliferation of online pharmacy distribution channels, a heightened focus on patient-centric pain management approaches, and the expansion of outpatient and ambulatory care facilities. Furthermore, major trends anticipated in this period include the rising prevalence of shingles within the aging population, a growing preference for non-opioid pain management therapies, the increasing utilization of transdermal and topical pain relief solutions, a greater demand for long-term chronic pain management strategies, and improved awareness coupled with earlier diagnosis of phn.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Underlying Factors Are Accelerating The Growth Of The Postherpetic Neuralgia (PHN) Market?

The escalating occurrence of chronic pain conditions is projected to fuel the expansion of the postherpetic neuralgia (PHN) market in the foreseeable future. Chronic pain is defined as pain that persists or recurs for over 3 months, frequently extending beyond the typical duration of an illness or injury and negatively impacting an individual’s daily activities and overall well-being. The widespread presence of chronic pain conditions stems from the aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which result in ongoing pain. Postherpetic neuralgia serves as a valuable area for chronic pain research because it offers a distinct model for investigating nerve-related pain processes and assessing extended treatment approaches. For example, a report released in January 2024 by the Office for Health Improvement and Disparities, a UK government body, indicated that approximately 18.4% of individuals aged 16 and above reported experiencing a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the rising occurrence of chronic pain conditions is a significant factor propelling the expansion of the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Divided Into Its Major Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

How Are Trends Transforming The Postherpetic Neuralgia (PHN) Market Landscape?

Major companies in the postherpetic neuralgia (PHN) market are concentrating on obtaining regulatory clearances to expand their product lines, gain a competitive edge, and address the considerable unmet clinical need for more effective and tolerable treatments. Regulatory approvals refer to the official authorizations issued by government health authorities that allow a drug or therapy to be legally sold and used for a specific medical condition. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, secured final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a type of neuropathic pain arising from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing starts at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

Who Are The Prominent Organizations Shaping The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Read the full postherpetic neuralgia (phn) market report here:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is Projected To Dominate The Postherpetic Neuralgia (PHN) Market During The Forecast Period?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Postherpetic Neuralgia (PHN) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the postherpetic neuralgia (phn) market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Postherpetic Neuralgia (PHN) Market between 2026 and 2030?

The postherpetic neuralgia (phn) market size has shown significant expansion in recent years. This market is anticipated to increase from $0.77 billion in 2025 to $0.82 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical growth can be attributed to several factors, including the rising incidence of herpes zoster infections, the limited array of treatment options for neuropathic pain, the continued reliance on opioid-based pain management, an expanding elderly population, and the progressive expansion of hospital pain management services.

The postherpetic neuralgia (phn) market is poised for robust expansion over the next few years. It is expected to grow to $1.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period can be attributed to factors such as the development of targeted neuropathic pain therapies, increasing adoption of biologic and branded drugs, the proliferation of online pharmacy distribution channels, a heightened focus on patient-centric pain management, and the expansion of outpatient and ambulatory care facilities. Notable trends for the forecast period include a rising prevalence of shingles in the aging population, increasing adoption of non-opioid pain management therapies, the growing use of transdermal and topical pain relief solutions, a higher demand for long-term chronic pain management, and improved awareness leading to early diagnosis of phn.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Postherpetic Neuralgia (PHN) Market?

The market for postherpetic neuralgia (PHN) is projected to grow, driven by the rising occurrence of chronic pain conditions. Chronic pain is defined as ongoing or intermittent discomfort that persists for over 3 months, frequently extending past the typical recovery period from an illness or injury, thereby impacting an individual’s daily activities and overall well-being. The higher incidence of chronic pain conditions can be attributed to an aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which cause enduring pain. Postherpetic neuralgia serves as a valuable subject for chronic pain research, offering a distinct model for investigating nerve-related pain mechanisms and assessing long-term therapeutic approaches. As an illustration, a report from the UK government’s Office for Health Improvement and Disparities in January 2024 indicated that approximately 18.4% of individuals aged 16 and over reported a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the expanding occurrence of chronic pain conditions is fueling the growth within the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Organized Into Various Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

Which Trends Are Influencing The Performance And Direction Of The Postherpetic Neuralgia (PHN) Market?

Leading companies in the postherpetic neuralgia (PHN) market are concentrating on securing regulatory approvals to expand their product portfolios, gain a competitive edge, and fulfill the substantial unmet clinical requirement for more effective and tolerable treatments. Regulatory approvals are the official permissions granted by government health authorities, enabling a drug or treatment to be legally commercialized and used for a specific medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, achieved final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are designed for treating PHN, a form of neuropathic pain caused by nerve damage from the reactivation of the varicella-zoster virus. For PHN, the customary dosage commences at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as necessary for pain alleviation.

Who Are The Core Companies Influencing Trends In The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Regions Are Projected To Dominate The Postherpetic Neuralgia (PHN) Market In The Coming Years?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Postherpetic Neuralgia (PHN) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Postherpetic Neuralgia (PHN) Market Size Likely To Evolve From 2025 Through 2034?

The market size for postherpetic neuralgia (phn) has shown robust growth over recent years. It is anticipated to expand from $0.72 billion in 2024 to $0.77 billion in 2025, at a compound annual growth rate (CAGR) of 7.0%. The expansion observed in the past can be linked to an increase in the incidence of herpes zoster infections, an expanding older adult population, heightened awareness among both patients and healthcare providers, a growing need for effective neuropathic pain management strategies, and rising healthcare spending.

The postherpetic neuralgia (PHN) market size is set to experience significant expansion in the coming years. It is projected to reach $0.99 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth can be attributed to the increasing utilization of antiviral medications and vaccines, the rising prevalence of chronic pain disorders, the growing adoption of advanced drug delivery systems, an increase in clinical trials and research and development investments, and more regulatory approvals for new therapeutics. Prominent trends throughout the forecast period include advancements in neuropathic pain research, innovations in drug delivery technologies, technology-driven diagnostic tools, the integration of artificial intelligence in clinical trials, and progress in non-opioid pain management alternatives.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

Which Drivers Are Impacting The Postherpetic Neuralgia (PHN) Market?

The growing occurrence of chronic pain conditions is projected to boost the expansion of the postherpetic neuralgia (PHN) market in the future. Chronic pain is defined as ongoing or recurrent discomfort enduring for over three months, frequently extending past the typical duration of an ailment or injury, thereby impacting an individual’s daily activities and overall well-being. The widespread nature of chronic pain stems from the aging demographic, given that seniors are more susceptible to degenerative conditions such as arthritis and neuropathy, which result in persistent discomfort. Postherpetic neuralgia is valuable in chronic pain research, offering a distinct model for investigating nerve-related pain mechanisms and assessing long-term therapeutic approaches. For instance, a January 2024 report from the UK government’s Office for Health Improvement and Disparities indicated that approximately 18.4% of individuals aged 16 and above reported a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the rising prevalence of chronic pain conditions is fueling the expansion of the postherpetic neuralgia (PHN) market.

What Are The Leading Segments Analyzed In The Postherpetic Neuralgia (PHN) Market?

The postherpetic neuralgia (PHN) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Nicotine Patches, Hormone Replacement Therapy Patches, Analgesic Patches, Orthopedic Support Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Key Innovation Trends Are Fueling Advancements In The Postherpetic Neuralgia (PHN) Market?

Leading companies operating in the postherpetic neuralgia (PHN) market are actively pursuing regulatory clearances to expand their product portfolios, gain a competitive advantage, and address the significant unmet clinical need for more effective and tolerable treatments. Regulatory approvals denote the official permissions granted by government health authorities that allow a drug or therapy to be legally marketed and utilized for a specific medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, secured final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, a form of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing commences at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as needed for pain relief.

Which Major Industry Participants Are Leading The Postherpetic Neuralgia (PHN) Market Growth?

Major companies operating in the postherpetic neuralgia (PHN) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Is Projected To Lead The Postherpetic Neuralgia (PHN) Market During The Forecast Period?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in the postherpetic neuralgia (PHN) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Postherpetic Neuralgia (PHN) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2025, By The Business Research Company

Neuralgia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Postherpetic Neuralgia (PHN) Industry?

The market size for postherpetic neuralgia (phn) has significantly expanded in the past few years. It is expected to increase from a value of $0.72 billion in 2024 to $0.77 billion in 2025, marking a compound annual growth rate (CAGR) of 7.0%. This growth during the historical period can be credited to factors such as the rising number of herpes zoster infection cases, an aging population, heightened awareness among both patients and healthcare professionals, a growing demand for efficient solutions to manage neuropathic pain, and an increase in healthcare spending.

The market for postherpetic neuralgia (phn) is projected to experience substantial expansion in the forthcoming years, rising to $0.99 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period could be due to the increased utilization of antiviral medications and vaccines, a growing incidence of chronic pain disorders, rising implementation of sophisticated drug delivery systems, an increase in clinical trials and investment in research and development, and a surge in regulatory approvals for innovative therapeutics. Looking forward, the market trends will be driven by progress in neuropathic pain research, evolution in drug delivery technologies, advances in technology-enabled diagnostic aids, the application of artificial intelligence in clinical trials, and progress in non-opioid pain control alternatives.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Forces Are Driving The Growth Of The Postherpetic Neuralgia (PHN) Industry?

The anticipated surge in the postherpetic neuralgia (PHN) market is primarily ascribed to the growing incidence of chronic pain conditions. Chronic pain, which typically lasts longer than three months, tends to be persistent or recurrent, often surpassing the average course of a disease or injury and compromising an individual’s daily activities and overall quality of life. The increased emergence of chronic pain conditions is a consequence of an aging population, as elderly individuals are more susceptible to degenerative diseases such as arthritis and neuropathy, ultimately resulting in persistent pain. Postherpetic neuralgia contributes significantly to chronic pain research, providing an explicit model to explore mechanisms behind nerve-related pain and evaluate enduring treatment tactics. For instance, in January 2024, a report issued by the Office for Health Improvement and Disparities, a governmental department based in UK, disclosed that approximately 18.4% of people aged 16 and above reported suffering from a long-term musculoskeletal (MSK) condition in 2023, presenting an increase from 17.6% the previous year. Consequently, the escalating rates of chronic pain conditions are bolstering the progress of the postherpetic neuralgia (PHN) market.

What Is The Overview Of Market Segmentation In The Postherpetic Neuralgia (PHN) Industry?

The postherpetic neuralgia (PHN) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Nicotine Patches, Hormone Replacement Therapy Patches, Analgesic Patches, Orthopedic Support Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Future Market Trends Are Projected For The Postherpetic Neuralgia (PHN) Industry?

Primary businesses in the postherpetic neuralgia (PHN) sector are working diligently to secure regulatory clearances. These approvals help diversify their product range, give them a competitive edge, and address the substantial unmet healthcare requirement for more effective and bearable treatments. These clearances are the official consents provided by government health bodies that authorize the legal marketing and utilization of a medication or remedy for a specific health issue. To illustrate, Zydus Lifesciences Ltd., a pharmaceutical firm based in India, secured the final approval from the United States Food and Drug Administration in February 2023. This permitted the company to produce and sell once-per-day generic Gabapentin Tablets, available in 300 mg and 600 mg doses, for the treatment of postherpetic neuralgia (PHN). These Gabapentin tablets are designed to manage PHN, a type of neuropathic discomfort caused by nerve damage following the reactivation of the varicella-zoster virus. For PHN, the recommended dosage begins at 300 mg on day one, goes up to 600 mg (twice a day at 300 mg) on the second day, and reaches 900 mg (three times a day at 300 mg) on the third day. The dosage can be increased up to 1800 mg daily (600 mg three times a day) as required for alleviating pain.

Who Are The Primary Players Operating Across The Global Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (PHN) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Offers The Most Growth Potential For The Postherpetic Neuralgia (PHN) Market Through 2029?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in the postherpetic neuralgia (PHN) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model